白衣效应和高血压对动脉硬度的相互作用
Lin Jin1, Zhenyi Li1, Xinyi Li2,3
1Department of Ultrasound, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine.
Journal of hypertension
|February 6, 2026
概括
白外套效应 (WCE) 与高血压患者的动脉硬性增加和心血管疾病 (CVD) 风险增加有关. 这项研究发现,WCE独立地预测了更大的动脉硬性,特别是在女性中.
科学领域:
- 心脏病学 心脏病学
- 高血压研究 高血压研究
- 血管生物学 血管生物学
背景情况:
- 白外套效应 (WCE),在临床环境中以高血压为特征,是争论的心血管疾病 (CVD) 风险因素.
- 关于WCE,高血压和动脉硬之间的关联现有研究仍然不一致,需要进一步调查.
研究的目的:
- 为了研究WCE和高血压之间有关动脉硬性的相互作用.
- 确定WCE是否是动脉硬和心血管疾病风险的独立预测因素.
主要方法:
- 包括对照组和高血压患者在内的7584名参与者被分为四组:对照组,白袍高血压 (WCH),高血压和白袍不受控制的高血压 (WUCH).
- 使用动脉速度脉冲指数 (AVI) 和动脉压量指数 (API) 通过袖子振荡计来评估动脉硬度.
- 使用后勤回归和限制性立方线 (RCS) 分析来评估风险因素和API-脉冲压力关系.
主要成果:
- 与WCH患者相比,WUCH患者的年龄较大,脉压 (PP) 和API都较高.
- 在多变量分析中,WCH/WUCH和API都被确定为动脉硬的独立决定因素和高心血管疾病风险的显著预测因素.
- 在WCE和非WCE个体中观察到API和PP之间存在显著的J形关系.
结论:
- 经历白色外套效应的个体表现出外围动脉硬度增加,女性表现更为明显.
- 该研究证实WCE是与心血管疾病风险增加相关的独立风险因素.
- 无论WCE状态如何,动脉硬度指数 (API) 和脉冲压 (PP) 之间存在一个J形的关联.
关键词:
在这里,我们可以使用API API API.在AVI AVI AVI中使用.这就是为什么BMI是BMI.这就是为什么B.P.B.B.B.在CVD中,CVD是非常重要的.DBP DBP DBP 的意思是说.在FCVRS中使用FCVRS.弗雷明汉心血管风险评分在HDL-C中使用.人力资源部的人力资源部这是一个MAP MAP.这就是为什么PPPPPPPPPPPPPP在SBP中使用SBP.在TCT上,TCT就是TCT.在WCE中,WCE是WCE.这就是为什么WCH WCH这就是WUCH WUCH.动脉压力体积指数动脉硬性 动脉硬性动脉速度脉冲指数动脉速度指数血压 血压 血压 血压身体质量指数 (BMI) 是指身体质量指数.心血管疾病心血管疾病腹静止血压的压力 腹静止血压心率的心跳是如何发生的.高密度脂蛋白胆固醇高密度脂蛋白胆固醇的使用平均动脉压力是指动脉的压力.脉冲压力 脉冲压力 脉冲压力压缩性血压 压缩性血压是一种血压.总胆固醇总的胆固醇.白色外套的效果是什么白外套高血压是什么意思白外套 没有控制的高血压
相关概念视频
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
615
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
615
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
477
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
477
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
512
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
512
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
628
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
628
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
550
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
550
01:28Hypertension I: Introduction
911
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
911